透析服务商达维塔保健(DVA)股价在10月30日盘中出现12.67%的暴跌,引发市场广泛关注。这一暴跌主要归咎于公司第三季度业绩不佳、利润大幅下滑。
达维塔保健当日公布的最新财报显示,第三季度公司营收32.6亿美元,符合预期。但受高昂的患者护理成本拖累,调整后每股收益仅为2.59美元,远低于分析师预期的2.73美元。数据显示,该季度达维塔保健每次治疗病人的护理成本达到257.46美元,同比有所上涨。
作为一家领先的透析服务提供商,病人护理成本一直是达维塔保健的主要运营支出。但本季度这一成本的失控导致公司利润率水平大幅下滑,引发投资者对其未来业绩前景的担忧。分析普遍预计,居高不下的患者护理成本问题很可能在第四季度持续,进而继续影响公司的盈利能力。投资者的看空预期最终引发了公司股价在盘中暴跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.